The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...

(NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine ...

The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic ...

Anxiety can cause symptoms that affect different body systems and may range from nervousness to feelings of dread and panic. Some symptoms may be longer lasting. Most people experience occasional ...

Over the past few years, more effective therapies have emerged in the treatment of chronic lymphocytic leukemia (CLL); these are mainly combinations of immunotherapy with fludarabine-based regimens.

These advances have expanded the treatment landscape for chronic lymphocytic leukemia (CLL), offering both time-limited and continuous therapy options tailored to the needs of individual patients. In ...

Treatment discontinuation due to AEs was more ... preferred therapeutic options in the setting of relapsed/refractory CLL,” the researchers concluded. Disclosures: There was no funding for ...

The goal in treating ulcerative colitis is to reduce the inflammation, hopefully leading to remission. The two leading treatment options are medication and surgery. Approximately 70 percent of ...

The devastating disease also quickly escalates through persistent and worsening symptoms as it infects white blood cells throughout the body. ALL is generally believed to be more common in boys ...

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment. Cyrus M. Khan, MD, hematologist in the Division of Hematology and Cellular ...